- Cefmenoxime
-
- $30.00/ kg
-
2024-03-31
- CAS:65085-01-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000000
- Cefmenoxime
-
- $240.00 / 1KG
-
2023-11-30
- CAS:65085-01-0
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 9000kg/per week
- Cefmenoxime
-
- $0.00 / 25KG
-
2023-06-20
- CAS:65085-01-0
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
|
| | Cefmenoxime Basic information |
| Product Name: | Cefmenoxime | | Synonyms: | CEFMENOXIME;(6r-(6alpha,7beta(z)))-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid;(6R,7R)-7-[[(Z)-(2-Aminothiazol-4-yl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(6R,7R)-7α-[2-(2-Amino-4-thiazolyl)-2-[(Z)-methoxyimino]acetylamino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;7β-[[(Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazole-5-yl)thio]methyl]cepham-3-ene-4-carboxylic acid;CMX;(6R,7R)-7-[(2E)-2-(2-aMino-1,3-thiazol-4-yl)-2-(MethoxyiMino)acetaMido]-3-{[(1-Methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]Methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,7β(Z)]]- | | CAS: | 65085-01-0 | | MF: | C16H17N9O5S3 | | MW: | 511.56 | | EINECS: | 278-299-4 | | Product Categories: | Pharmaceutical intermediate | | Mol File: | 65085-01-0.mol |  |
| | Cefmenoxime Chemical Properties |
| | Cefmenoxime Usage And Synthesis |
| Originator | Tacef,Takeda,W. Germany,1983 | | Uses | Antibacterial. | | Uses | Cefmenoxime (cas# 65085-01-0) is a compound useful in organic synthesis. | | Definition | ChEBI: A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position. | | Manufacturing Process | 7β-[α-Methoxyimino-α-(2-aminothiazol-4-yl)acetamido]cephalosporanicacid
trifluoroacetic acid salt is dissolved in a solution of 272 mg of 1-methyl-5-
mercapto-1H-tetrazole, 555 mg of sodium bicarbonate and 68 mg of
triethylbenzylammonium bromide in 10 ml of water. The solution is heated at
60°C in nitrogen atmosphere for 6 hours. After cooling, the reaction solution
is passed through a column of Amberlite XAD-2 and eluted with water and
then with 2.5% ethanol. The procedure yields sodium 7β-[α-methoxyimino-α-
(2-aminothiazol-4-yl)acetamido]-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3-
cephem-4-carboxylate, MP 174°C to 175°C (decomposition). | | Brand name | Cefmax (TAP). | | Therapeutic Function | Antibacterial | | Antimicrobial activity | A semisynthetic cephalosporin supplied as the hydrochloride.
Its activity is very similar to that of cefotaxime. A
500 mg intramuscular injection achieves a plasma concentration
of 15 mg/L after 40 min. A concentration of 200 mg/L is
attained after intravenous administration of 1 g. The plasma
half-life is c. 1 h. Around 77% is protein bound. Probenecid
increases peak plasma levels and extends the plasma half-life
to 1.8 h. Therapeutic concentrations are achieved in CSF.
There is a degradation product with a long half-life (around
40 h), but 80–92% of the drug is recovered unchanged from
the urine. In patients with renal insufficiency, no significant
relation was found between creatinine clearance and peak
serum concentrations but there was a linear relationship
with plasma half-life and total body clearance. About 10%
of the dose appears in the feces, mostly extensively degraded,
possibly
by the fecal flora.
Toxicity, side effects and clinical use are those common to
group 4 cephalosporins. |
| | Cefmenoxime Preparation Products And Raw materials |
|